Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue.

We have developed an expandable modular body-on-a-chip system that allows for a plug-and-play approach with several in vitro tissues. The design consists of single-organ chips that are combined with each other to yield a multi-organ body-on-a-chip system. Fluidic flow through the organ chips is driven via gravity and controlled passively via hydraulic resistances of the microfluidic channel network. Such pumpless body-on-a-chip devices are inexpensive and easy to use. We tested the device by culturing GI tract tissue and liver tissue within the device. Integrated Ag/AgCl electrodes were used to measure the resistance across the GI tract cell layer. The transepithelial resistance (TEER) reached values between 250 to 650 Ω cm(2) throughout the 14 day co-culture period. These data indicate that the GI tract cells retained their viability and the GI tract layer as a whole retained its barrier function. Throughout the 14 day co-culture period we measured low amounts of aspartate aminotransferase (AST, ∼10-17.5 U L(-1)), indicating low rates of liver cell death. Metabolic rates of hepatocytes were comparable to those of hepatocytes in single-organ fluidic cell culture systems (albumin production ranged between 3-6 μg per day per million hepatocytes and urea production ranged between 150-200 μg per day per million hepatocytes). Induced CYP activities were higher than previously measured with microfluidic liver only systems.

[1]  Peter F. Davies,et al.  Shear Stress Biology of the Endothelium , 2005, Annals of Biomedical Engineering.

[2]  Jiajie Yu,et al.  In vitro 3D human small intestinal villous model for drug permeability determination. , 2012, Biotechnology and bioengineering.

[3]  D. Ingber,et al.  Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. , 2012, Lab on a chip.

[4]  Malorye Allison,et al.  Reinventing clinical trials , 2012, Nature Biotechnology.

[5]  R. Hajar,et al.  Animal Testing and Medicine , 2011, Heart views : the official journal of the Gulf Heart Association.

[6]  G. Betton,et al.  The predictivity of the toxicity of pharmaceuticals in humans from animal data--an interim assessment. , 1998, Toxicology letters.

[7]  Tongtong Liu,et al.  Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Mandy B. Esch,et al.  How multi-organ microdevices can help foster drug development. , 2014, Advanced drug delivery reviews.

[9]  H. Ferdowsian,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[10]  F. Sonntag,et al.  A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. , 2015, Lab on a chip.

[11]  Yasuyuki Sakai,et al.  Enhanced cytochrome P450 capacities of Caco-2 and Hep G2 cells in new coculture system under the static and perfused conditions : evidence for possible organ-to-organ interactions against exogenous stimuli , 2004 .

[12]  J. Arrowsmith Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[13]  Jiajie Yu,et al.  Three dimensional human small intestine models for ADME-Tox studies. , 2014, Drug discovery today.

[14]  Thomas Hartung,et al.  Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice , 2013, Archives of Toxicology.

[15]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[16]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[17]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[18]  Mone Zaidi,et al.  Molecular regulation of mechanotransduction. , 2005, Biochemical and biophysical research communications.

[19]  Leslie Z. Benet,et al.  Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .

[20]  E. Leclerc,et al.  Investigation of ifosfamide nephrotoxicity induced in a liver–kidney co‐culture biochip , 2013, Biotechnology and bioengineering.

[21]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[22]  L. Griffith,et al.  Bioreactor technologies to support liver function in vitro. , 2014, Advanced drug delivery reviews.

[23]  Y. Berger,et al.  The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications , 1995, Cell Biology and Toxicology.

[24]  M. Shuler,et al.  Quantification of chemical–polymer surface interactions in microfluidic cell culture devices , 2009, Biotechnology progress.

[25]  Thomas Singer,et al.  A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. , 2013, Toxicology and applied pharmacology.

[26]  K. Hillgren,et al.  In vitro systems for studying intestinal drug absorption , 1995, Medicinal research reviews.

[27]  Aaron Sin,et al.  Development of a Microscale Cell Culture Analog To Probe Naphthalene Toxicity , 2008, Biotechnology progress.

[28]  S. Basu,et al.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. , 2011, Journal of pharmaceutical sciences.

[29]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[30]  Michael L Shuler,et al.  Incorporation of 3T3‐L1 Cells To Mimic Bioaccumulation in a Microscale Cell Culture Analog Device for Toxicity Studies , 2008, Biotechnology progress.

[31]  Jiajie Yu,et al.  On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’ devices , 2012, Biomedical microdevices.

[32]  J. March,et al.  3-D Intestinal Scaffolds for Evaluating the Therapeutic Potential of Probiotics , 2014, Molecular pharmaceutics.

[33]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[34]  I. Cuthill,et al.  Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.

[35]  Jeffrey M. Perkel LIFE SCIENCE TECHNOLOGIES: Animal-Free Toxicology: Sometimes, in Vitro is Better , 2012 .

[36]  G. Nicolaysen,et al.  Interstitial fluid volume: local regulatory mechanisms. , 1981, Physiological reviews.

[37]  Mandy B. Esch,et al.  Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity , 2009, Biotechnology and bioengineering.

[38]  Gretchen J. Mahler,et al.  Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. , 2009, The Journal of nutritional biochemistry.

[39]  G Mannens,et al.  Strategies for absorption screening in drug discovery and development. , 2001, Current topics in medicinal chemistry.

[40]  Laurent Griscom,et al.  Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. , 2012, Toxicology and applied pharmacology.

[41]  Michael L Shuler,et al.  A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers , 2009, Biotechnology and bioengineering.

[42]  Eric Leclerc,et al.  First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans , 2014, Biotechnology and bioengineering.

[43]  Jong Hwan Sung,et al.  A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. , 2010, Lab on a chip.

[44]  Michael L Shuler,et al.  Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow. , 2015, Lab on a chip.

[45]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[46]  Hanry Yu,et al.  Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. , 2009, Lab on a chip.

[47]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[48]  Mandy B. Esch,et al.  Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. , 2014, Lab on a chip.